Fibrocell Science, Inc. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Revenue from product sales
Collaboration revenue
Total revenues
Cost of product sales
Cost of collaboration revenue
Total cost of revenue
Gross loss
Research and development expenses
Affiliated Entity
Total research and development expenses
Selling, general and administrative expenses
Intangible asset impairment expense
Restructuring costs
Total operating expenses
Other income (expense):
Warrant revaluation and other finance income (expense)
Other income
Loss from continuing operations before income taxes
Deferred tax benefit
Loss from continuing operations
Loss from discontinued operations, net of tax
Gain on sale of discontinued operations, net of tax
Warrant revaluation income
Derivative revaluation income (expense)
Interest expense
Other income (expense), net
Other income, net
Loss on extinguishment of debt

Loss before income taxes
Income taxes
Net loss
Net loss attributable to non-controlling interest
Dividend paid in-kind to preferred stockholders
Deemed dividend on preferred stock (see Note 8)
Net loss attributable to common stockholders
Net loss
Loss from continuing operations - basic
Gain on sale of discontinued operations, net of tax - basic
Basic (in dollars per share)
Loss from continuing operations - diluted
Gain on sale of discontinued operations, net of tax - diluted
Diluted (in dollars per share)

Weighted average number of common shares outstanding
Basic (in shares)
Diluted (in shares)

Comments